Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

NCT01421667 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01421667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01421667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
June 30, 2015
Enrollment
176 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, lymphoma, t-cell